Rockwell Medical Inc Dossier - Source-backed chat

Rockwell Medical Inc

RMTINASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.41

Intrinsic Value $7.57median of 2 methodsbased on filings through 31 Dec 2025

Market Price $8.57Price as of 1 Oct 2026

Near fair valueIntrinsic value is 12% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $34.5M

Enterprise Value $18.4M

Shares Outstanding 4M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rockwell Medical is successfully transitioning from a low-margin, highly concentrated supplier of hemodialysis concentrates to a diversified, profitable business. Despite a temporary decline in top-line revenue due to volume reductions from its largest customer, DaVita, the company is improving its gross margins and operational efficiencies. With pricing adjustments and streamlined distribution expected to generate over $3 million in annualized gross profit improvements, Rockwell is on track to achieve sustained profitability and positive operating cash flow in 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$30.00

High · most bullish analyst$40.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5515%

The company fails to onboard new customers quickly enough to offset the DaVita volume decline, or inflationary pressures on raw materials and distribution erode gross margins. The company fails to regain Nasdaq compliance, forcing a reverse stock split that negatively impacts retail investor sentiment.

Base CaseCentral scenario

$2.0065%

The company achieves its full-year 2026 guidance of $70M–$75M in net sales and 18%–22% gross margin. Operational efficiencies and pricing adjustments successfully offset the volume loss from DaVita, leading to positive Adjusted EBITDA of $1M–$2M and positive operating cash flow, eliminating the need for dilutive capital raises.

Bull CaseUpside scenario

$3.2310%

Rockwell signs a meaningful contract with a mid-sized dialysis provider or successfully expands its western U.S. footprint, driving 1-year revenue growth of +15% and accelerating profitability.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong progress toward sustained profitability with positive Adjusted EBITDA and positive operating cash flow guided for FY 2026.
Successful diversification of the customer base, reducing DaVita concentration from 27% in 2025 to 7% in Q1 2026.
Operational changes and pricing adjustments expected to generate over $3 million in annualized gross profit improvements.

Key Investment Risks

Nasdaq minimum bid price non-compliance risk, with a deadline of November 4, 2026, to regain compliance.
High historical customer concentration and the risk of further volume reductions from major dialysis providers.
Exposure to rising raw material, labor, and transportation costs if they cannot be passed on to customers.

Thesis Invalidation Triggers

Failure to achieve positive operating cash flow in FY 2026, leading to further dilutive equity financing.
Gross margins falling below the guided 18% range due to operational inefficiencies or cost inflation.
Inability to regain Nasdaq compliance, resulting in delisting from the Nasdaq Capital Market.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.